Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DESOGESTREL & ETHINYL ESTRADIOL

All products: general benefit

Other products in the same Health Canada class (G03A, G03AA) — coverage varies; not interchangeable

  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit
  • Ethinyl estradiol + norethindrone (Brevicon): general benefit
  • Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit
  • Drospirenone (Slynd): general benefit
  • Levonorgestrel (Plan B): general benefit

3 more in the class list below

Marvelon 21 · DIN 02042487 · 0.15mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Marvelon (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Marvelon 21 · DIN 02042487 Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01 Health Canada: Marketed since 2022-05-19 · brand MARVELON 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.2773 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14354 · Verify on the e-Formulary ↗ (DIN 02042487)

Source record
DIN 02042487: Marvelon 21 Raw flags: sec3=Y Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id ORG Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $22.1600; ministry $5.2773 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02042487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14354
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773 Freya 21 · DIN 02396491 · $5.2773 Miley 21 · DIN 02556553 · $5.2773 Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DROSPIRENONE & ETHINYL ESTRADIOL DROSPIRENONE & ETHINYL ESTRADIOL · General benefit • Conception Control PM: https://pdf.hres.ca/dpd_pm/00080997.PDF; date 2025-07-07; DIN 02261723; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & ETONOGESTREL · Off-Formulary Interchangeable, not an ODB benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077755.PDF; date DEC 12, 2004; DIN 02253186; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & LEVONORGESTREL · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) 1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. PM: https://pdf.hres.ca/dpd_pm/00081001.PDF; date 2025-07-07; DIN 00707503; fetched 2026-09-10 Product monograph NORETHINDRONE · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. PM: https://pdf.hres.ca/dpd_pm/00085300.PDF; date JUL 10, 2026; DIN 02410303; fetched 2026-09-10 Product monograph NORGESTIMATE & ETHINYL ESTRADIOL · Listed, not a benefit (4), General benefit (6) Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081457.PDF; date 2025-08-21; DIN 02401967; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS MARVELON® (desogestrel/ethinyl estradiol tablets, USP) is indicated for: • Conception control 1.1 Pediatrics Pediatrics: The safety and efficacy of MARVELON® has not been established in women under the age of 18 years. Use of this product before menarche is not indicated. 1.2 Geriatrics Geriatrics: MARVELON® is not indicated in postmenopausal women. https://pdf.hres.ca/dpd_pm/00077799.PDF PM date: NOV 20, 2024 Source product: MARVELON 28; DIN 02042479; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.